Fertility can return as early as 21 days after delivery. Yet postnatal contraception remains one of the most under-discussed aspects of maternity care, with many women leaving hospital without a clear plan for preventing an unintended pregnancy.
The UK government's renewed Women's Health Strategy, announced on 15 April 2026, commits to putting women's voices at the heart of healthcare decision-making. Contraceptive choice after birth — a decision shaped by breastfeeding status, medical history, lifestyle and personal preference — is precisely the kind of conversation that benefits from accessible, non-judgemental healthcare. Community pharmacy is well placed to deliver it.
The 21-day rule
The Faculty of Sexual and Reproductive Healthcare (FSRH) guidelines are clear: if contraception is not started by day 21 postpartum, additional precautions or abstinence are needed for the first 7 days of any hormonal method (or 2 days for the progestogen-only pill).
This creates a narrow window. Women who are discharged from hospital on day 1 or 2, and whose 6-week GP check is the next scheduled contact, face a gap of several weeks during which fertility may have returned without contraception in place.
Pharmacy can bridge that gap — through emergency contraception supply, progestogen-only pill provision, and counselling that helps women make an informed choice before the 6-week review.
Methods available and their postnatal timing
| Method | When it can start | Breastfeeding compatible? | Available via pharmacy? |
|---|---|---|---|
| Progestogen-only pill (POP) | From day 1 postpartum | Yes — no effect on milk supply | Yes (Hana, Lovima OTC; others via PGD/prescription) |
| Combined oral contraceptive (COC) | From day 21 if not breastfeeding; avoid until 6 weeks if breastfeeding | Not recommended in first 6 weeks of breastfeeding (FSRH) | Prescription only |
| Desogestrel POP (OTC) | From day 1 | Yes | Yes — Hana and Lovima available without prescription |
| Progestogen-only injectable | From day 21 | Yes | Via GP, sexual health clinic or pharmacy PGD |
| Intrauterine device (IUD/IUS) | Within 48 hours of delivery, or from 4 weeks | Yes | Fitted at GP or clinic, not pharmacy |
| Contraceptive implant | From day 1 | Yes | Fitted at GP or clinic |
| Condoms | Immediately | Yes | Yes |
| Emergency contraception | As needed | Levonorgestrel: yes; ulipristal: express and discard milk for 7 days (FSRH) | Yes — levonorgestrel OTC |
The pharmacy conversation
The most impactful role for community pharmacy is proactive counselling when a postnatal woman collects a prescription or purchases infant care products. Key messages include:
- Fertility returns earlier than most people expect. The belief that breastfeeding alone prevents pregnancy (lactational amenorrhoea method, LAM) is only reliable under strict conditions: exclusive breastfeeding, no periods returned, and baby under 6 months. Most UK women do not meet all three criteria.
- The desogestrel POP is available over the counter. Since Hana and Lovima were reclassified in 2021, women can obtain a progestogen-only pill from the pharmacy without a prescription. This is particularly useful in the early postnatal weeks before a GP appointment is arranged.
- Emergency contraception is safe during breastfeeding — levonorgestrel (Levonelle) does not require interruption of breastfeeding. Ulipristal (ellaOne) requires expressing and discarding milk for 7 days, making levonorgestrel the preferred choice for breastfeeding women.
- Long-acting methods (implant, IUS) are more effective but require a clinic visit. Pharmacy teams can signpost women to their GP or local sexual health service for fitting.
Common questions at the counter
"I'm breastfeeding — can I take the mini pill?"
Yes. The desogestrel POP (Hana, Lovima, or prescribed Cerazette/generics) is compatible with breastfeeding from day 1 postpartum. It does not affect milk supply or composition.
"I forgot to sort contraception and it's been more than 21 days — what do I do?"
If unprotected intercourse has occurred, emergency contraception may be appropriate. Levonorgestrel is available OTC and is breastfeeding-compatible. Start regular contraception at the same time and use condoms for the method-specific overlap period.
"When can I go back on the combined pill?"
If not breastfeeding: from day 21. If breastfeeding: FSRH recommends waiting until at least 6 weeks postpartum, with some guidance suggesting 6 months for fully breastfeeding women. The combined pill is associated with a small theoretical reduction in milk supply.
Data context
PharmSee tracks 1,742 active pharmacy vacancies across 11 sources. Of 491 NHS-listed pharmacy roles in the current dataset, sexual and reproductive health is rarely named as a specific competency in job descriptions — reflecting that postnatal contraception counselling is a general pharmacy skill, not a specialist post.
The availability of OTC desogestrel has shifted the postnatal contraception landscape since 2021. Pharmacy teams are now in a position to provide first-line hormonal contraception without a prescription, reducing the gap between delivery and effective contraceptive cover.
When to refer
Refer to the GP or sexual health clinic when:
- The woman wants a long-acting reversible method (LARC): implant, IUS, IUD or injectable
- There are contraindications to hormonal methods (e.g. history of VTE, which is elevated postpartum)
- The woman is within 21 days of delivery and wants the combined pill started (needs clinical assessment of VTE risk)
- Breastfeeding difficulties coincide with contraceptive concerns — joint review may be needed
Caveats
Contraceptive guidance follows FSRH UK Medical Eligibility Criteria (UKMEC) and FSRH clinical guidelines. Pharmacy supply of desogestrel POP is subject to the pharmacist's clinical assessment at the counter. Emergency contraception availability and local PGD arrangements vary by region. PharmSee tracks job vacancies, not contraceptive service provision, so the figures cited relate to workforce capacity rather than service availability.
Sources: Faculty of Sexual and Reproductive Healthcare (FSRH) guidelines, NICE Clinical Knowledge Summaries, MHRA OTC reclassification data, PharmSee vacancy database (April 2026), BBC News (15 April 2026).